Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- MYMD
- Price
- -
- Stock movement up
- +0.02 (1.46%)
- Company name
- MyMD Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 3.15M
- Ent value
- 28.62M
- Price/Sales
- -
- Price/Book
- 8.25
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -11.70%
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -67.47%
- 1 year return
- -92.08%
- 3 year return
- -82.03%
- 5 year return
- -71.56%
- 10 year return
- -65.03%
Last updated: 2024-12-17
DIVIDENDS
MYMD does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 8.25 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 2.37M |
| EPS (TTM) | -7.46 |
| FCF per share (TTM) | -4.09 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -13.40M |
| Net income (TTM) | -17.69M |
| EPS (TTM) | -7.46 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 536.03K |
| Net receivables | 0.00 |
| Total current assets | 14.36M |
| Goodwill | 10.50M |
| Intangible assets | 0.00 |
| Property, plant and equipment | 25.80K |
| Total assets | 26.38M |
| Accounts payable | 4.09M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 5.78M |
| Total liabilities | 26.00M |
| Shareholder's equity | 382.29K |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -9.67M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -9.69M |
| Dividends paid (TTM) | 1.13M |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -4626.36% |
| Return on Assets | -67.04% |
| Return on Invested Capital | -4626.36% |
| Cash Return on Invested Capital | -2534.77% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| MYMD | S&P500 | |
| Current price drop from All-time high | -100.00% | - |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 18 Sep 2024 | 9 Mar 2009 |
| Avg drop from high | -98.29% | -11.07% |
| Avg time to new high | 676 days | 12 days |
| Max time to new high | 2701 days | 1805 days |
COMPANY DETAILS
Marketcap
3.15M
Marketcap category
Small-cap
Description
MyMD Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Employees
6
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner